Results. A total of 36,828 DOT were included for 56 physicians at two hospitals. Prescriber rank changed for all top five prescribers at each hospital after incorporating physician-specific denominator metrics as compared with DOT alone (Table 1) . The largest change in rank observed was 19 spots using admissions as a denominator.
Background. Antimicrobial stewardship programs are recommended to risk-adjust antimicrobial use in order to support intra-and inter-hospital comparisons. The purpose of our investigation was to evaluate a benchmarking strategy for its ability to accurately identify changes in risk-adjusted utilization as a result of known stewardship interventions.
Methods. Antimicrobial drug use was measured as days of therapy (DOT) from billing records. Based on diagnosis-related group (DRG) assignment, we calculated expected (E) use determined by indirect standardization and compared with observed (O) use for three targeted groups of antimicrobials: anti-pseudomonals β-lactams; ceftriaxone; and fluoroquinolones. As a stewardship strategy, a clinical pharmacist-driven, individualized pseudomonal risk assessment based antibiotic prior authorization process was implemented in the third quarter of 2016, focusing on commonly encountered community-onset infections.
Results. The 10-month time period prior to implementing the intervention was used to establish the benchmark with over 10,000 billing records. Utilization assigned to DRGs from this time period was used to predict expected utilization. As a result of the intervention, a decrease in anti-pseudomonal agent utilization at the cost of an increase in ceftriaxone utilization was observed (Figure 1) , with the lack of a significant impact toward change in the utilization of the fluoroquinolones. Variability in use is explained by the treated patients within each DRG.
Conclusion. Antibiotic utilization was benchmarked to expected use adjusted for patient mix based on DRGs, and trends in changing antibiotic consumption were correctly identified. Differences between expected and observed use reflect usage patterns that take into consideration type of patients treated and provides the basis of evaluation of outcome measures for our stewardship interventions. Background. The standardized antimicrobial administration ratio (SAAR) compares each hospital's observed to predicted days of antimicrobial therapy. However, confusion exists about how hospital-level, seasonal, and hospital-peer-based variations in antibiotic use might impact an institution's SAAR. We characterized the impact of each of these three types of variation on predicted SAARs utilizing local NHSN data.
Understanding the Components and Calculation of the SAAR, Illustrative Data
Methods. Analysis of antibiotic consumption data from an academic medical center in Chicago, IL was conducted. SAAR and antimicrobial days per 1,000 days present (AD/1,000DP) were compiled in monthly increments from 2014 to 2016. Antimicrobial consumption was aggregated and classified into agent categories according to NHSN criteria. Month-to-month changes in both the SAAR and AD/1,000DP were evaluated. Azithromycin AD/1,000DP from 2012 through 2017 were explored for seasonal variation as defined as >20% increase in AD/1,000DP from each quarter to the overall mean AD/1,000DP for all months. A simulation was performed to explore the potential effect of seasonality on the SAAR. Demographic covariates within the SAAR model were altered while holding constant observed antibiotic use; thus we were able to observe the potential impact of demographics. Finally, a simulation explored the effect of altered consumption at other hospitals on a local institution's SAAR.
Results. Across all antibiotic agent categories for both ICU (n = 4) and general wards (n = 4), the average matched-month percent change in AD/1,000DP was highly predicted and correlated with the corresponding change in SAAR (Figure 1 , Pearson's r = 0.99). The monthly mean ± SD AD/1,000DP was 235.0 (range 47.2-661.5), and the mean ± SD SAAR was 1.09 ± 0.26 (range 0.79-1.09) across the NHSN antibiotic agent categories. Five quarters were found to have seasonal variation in AD/1000DP for azithromycin (Figure 2 ). Simulations demonstrated that changing antimicrobial usage at comparator hospitals does not impact the local SAAR, and seasonal variation may cause fluctuating SAARs.
Conclusion. Month-to-month changes in the SAAR mirror monthly changes in an institution's AD/1,000DP. Seasonal variation can impact the SAAR, and the effect changing peer hospital antibiotic consumption is not currently captured by the SAAR methodology.
